UPDATE: Jefferies Raises PT to $32 on Pacira Pharmaceuticals on Exparel Launch Momentum

By: Benzinga
Jefferies maintained Pacira Pharmaceuticals (NASDAQ: PCRX ) with a Buy rating and raised the price target from $24.00 to $32.00. Jefferies commented, "PCRX is heading into its 4th Q of Exparel launch with strong momentum. Exparel access and uptake continue to ramp (volume growth through end'12 looked parabolic) and PCRX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.